Anixa Biosciences 1 article

The company-level identity of Anixa Biosciences reflects lactation protein tumor antigen targeting, with FSH receptor CAR-T therapy contributing to how its vaccine platform is constructed or delivered. Its platform also incorporates follicle-stimulating hormone receptor targeting and ovarian cancer cellular immunotherapy, while cancer vaccine immune memory explains how antigen presentation, adjuvant activity or formulation influences the resulting immune response. GenoMethods separates the organization from antigen, adjuvant and named vaccine products; the platform profile of Anixa Biosciences also includes tumor-associated reproductive antigen targeting.